Vivani Medical Reports Q2 2026 Results and Business Update

GlobeNewswire·13 Aug 2026·

·Read original

2▲2 ▼0Impact / 5

Earnings Biotechnology

VANI ▲

NVO ▲

Summary · why it matters

Vivani Medical reported second quarter 2026 financial results and provided a business update, including full enrollment in its SLIM-1 Phase 1 trial of NPM-139, a semaglutide implant for chronic weight management. The company entered into a non-exclusive agreement with Novo Nordisk to evaluate NPM-139 and its NanoPortal technology, and expects the Cortigent-ClearOne merger to close in the third quarter of 2026, with the combined entity trading on Nasdaq under ticker CRGT. Cash, cash equivalents and restricted cash totaled $20.8 million as of June 30, 2026, up from $17.6 million at the end of 2025, while net loss for the quarter was $6.4 million compared to $7.1 million a year earlier. Top-line data from the SLIM-1 trial are expected in November 2026, and the company plans to submit an IND for a Phase 2 dose-ranging study in 2027.

Vivani Medical Inc. ▲

Novo Nordisk A/S ▲